# Batch 2 Validation Review

Date created: 2026-06-02

Status: CANDIDATE REVIEW

Purpose: validate Batch 2 Synthetic World-Level File Construction for FI-W08 through FI-W13 against locked File Inventory v1, Synthetic World-Level File Construction Plan v1, Batch 1 locked files, and locked world architecture.

This validation review does not create task prompts, expected outputs, golden responses, grader guidance, AutoQC responses, submission artifacts, post-world information, or additional synthetic file rows.

## Files Constructed

| File ID | Constructed file | Locked inventory row matched | Status |
| --- | --- | --- | --- |
| FI-W08 | `FI-W08_hd1-hd2-hospitalist-progress-documentation.md` | HD1-HD2 hospitalist progress documentation | VERIFIED |
| FI-W09 | `FI-W09_hd3-hospitalist-progress-documentation.md` | HD3 hospitalist progress documentation | VERIFIED |
| FI-W10 | `FI-W10_hd4-hospitalist-progress-documentation.md` | HD4 hospitalist progress documentation | VERIFIED |
| FI-W11 | `FI-W11_hd5-hd6-hospitalist-discharge-planning-progress-documentation.md` | HD5-HD6 hospitalist discharge-planning progress documentation | VERIFIED |
| FI-W12 | `FI-W12_objective-renal-infection-hemodynamic-trend-summary-source.md` | Objective renal / infection / hemodynamic trend summary source | VERIFIED |
| FI-W13 | `FI-W13_medication-administration-inpatient-medication-action-source.md` | Medication administration / inpatient medication action source | VERIFIED |

Constructed file count: 6.

Authorized Batch 2 file IDs: FI-W08 through FI-W13.

Unauthorized synthetic files created: none.

## Locked Row Purpose Mapping

### VERIFIED

Finding: FI-W08 maps to its locked row purpose.

Evidence: the file shows HD1-HD2 early response, stabilization, evolving diagnostic frame, and initial medication-safety reasoning while preserving sepsis anchoring and cardiorenal medication uncertainty.

Impact: supports Traps #2 and #4 without over-resolving early diagnosis or medication restart decisions.

Action required: candidate review should confirm no early-hospital note overuses FI-W06 before HD4.

### VERIFIED

Finding: FI-W09 maps to its locked row purpose.

Evidence: the file shifts attention from acute stabilization toward functional and cognitive concerns on HD3 while keeping detailed functional evidence deferred to later nursing/PT/OT/family sources.

Impact: supports Trap #3 and Trap #4 without becoming the final functional or disposition answer.

Action required: preserve later FI-W17-FI-W21 as the main functional/cognitive evidence substrate.

### VERIFIED

Finding: FI-W10 maps to its locked row purpose.

Evidence: the file surfaces consultant tension, steroid-history inconsistency, FI-W06 availability by HD4, and hospitalist synthesis burden without treating any source as a complete answer.

Impact: supports Traps #1, #2, and #4 plus all three frictions.

Action required: later consultant files should remain defensible and time-sensitive.

### VERIFIED

Finding: FI-W11 maps to its locked row purpose.

Evidence: the file shows medical improvement and plausible discharge planning on HD5-HD6 while preserving functional, family, consultant, steroid, medication, and trend uncertainty.

Impact: establishes Trap #5 as a visible but incomplete discharge-facing physician source.

Action required: later FI-W22 must remain useful but incomplete rather than duplicating FI-W11 or becoming an answer file.

### VERIFIED

Finding: FI-W12 maps to its locked row purpose.

Evidence: the file provides objective renal, infection, hemodynamic, glucose, and intake trends through world close while explicitly separating baseline anchors from hospital-course values.

Impact: supports improvement-versus-persistence reasoning without deciding medication restart, steroid contribution, infection source, or discharge readiness.

Action required: candidate review should verify values remain realistic and not over-determinative.

### VERIFIED

Finding: FI-W13 maps to its locked row purpose.

Evidence: the file records inpatient medication actions, holds, continuations, and reassessment opportunities without creating a discharge medication list or final restart plan.

Impact: supports medication reconciliation, Trap #1, Trap #2, and consultant-friction reasoning.

Action required: preserve insulin lispro as inpatient-only logic and never count it as baseline medication architecture.

## Temporal Validation

### VERIFIED

Finding: no post-world information is present.

Evidence: FI-W08 through FI-W13 are anchored from HD1 through 05/23/2026 at 18:00 or earlier. No file includes discharge-day outcome, +7 information, +30 information, or later follow-up.

Impact: closed-world discipline is preserved.

Action required: none before candidate review.

### VERIFIED

Finding: FI-W06 timing constraint is preserved.

Evidence: FI-W08 and FI-W09 do not use outpatient rheumatology provenance as already available. FI-W10 introduces FI-W06 only on HD4, matching the locked availability constraint.

Impact: future clinicians cannot use rheumatology provenance before it exists in-world.

Action required: preserve this sequence in later consultant and discharge-facing files.

## Trap Preservation Validation

### VERIFIED

Finding: Trap #1 remains active and reconstructable.

Evidence: FI-W10 and FI-W13 reference prednisone source hierarchy and inpatient action ambiguity without proving actual pre-admission adherence or final steroid plan.

Impact: prednisone remains a source-of-truth trap rather than an answer hidden in one note.

Action required: later FI-W16 and FI-W20 should preserve the same hierarchy.

### VERIFIED

Finding: Trap #2 substrate is strengthened.

Evidence: FI-W08, FI-W10, FI-W11, FI-W12, and FI-W13 distribute early holds, improving renal/hemodynamic trends, medication-action history, and consultant-tension context.

Impact: medication restart reasoning now requires synthesis across trends, MAR/action source, and later consultant files.

Action required: later FI-W14 and FI-W15 should not make one specialty automatically correct.

### VERIFIED

Finding: Trap #3 and Trap #5 remain distinct.

Evidence: FI-W09 and FI-W11 acknowledge functional/cognitive and discharge-source issues but do not replace later nursing/PT/OT/family/care-coordination sources. FI-W11 is a visible but incomplete discharge-facing source; FI-W09 is an early physician summary that can underweight buried functional detail.

Impact: Trap #3 remains about finding buried functional/cognitive evidence; Trap #5 remains about not over-trusting a visible discharge-facing artifact.

Action required: later FI-W17-FI-W22 must preserve this split.

### VERIFIED

Finding: Trap #4 remains active.

Evidence: FI-W08 through FI-W12 preserve the reasonableness of early infection framing while showing that improvement does not resolve weakness, steroid uncertainty, medication timing, or disposition safety.

Impact: sepsis anchoring remains a partial-improvement trap, not a retrospective correction that sepsis was wrong.

Action required: none before candidate review.

## Friction Preservation Validation

### VERIFIED

Finding: Cardiology vs Nephrology remains balanced.

Evidence: FI-W10, FI-W11, FI-W12, and FI-W13 preserve both long-term HFrEF/CAD protection and renal/hemodynamic/potassium/volume-safety concerns.

Impact: neither specialty position collapses into obvious correctness.

Action required: later consultant files must preserve defensible disagreement and temporal context.

### VERIFIED

Finding: Family vs Primary Team remains balanced.

Evidence: FI-W09 and FI-W11 preserve the team's medical-improvement reasoning while retaining family baseline concerns and functional/cognitive uncertainty.

Impact: discharge remains plausible but not safely solved.

Action required: later nursing, therapy, family, and case-management files should deepen the evidence without making discharge obviously safe or unsafe.

### VERIFIED

Finding: Endocrinology vs Primary Team remains balanced.

Evidence: FI-W10 and FI-W11 preserve steroid-risk concern as reasonable while also preserving primary-team caution against over-attributing the case to steroid physiology.

Impact: steroid physiology remains important but not dominant.

Action required: later endocrinology file should remain interpretive, not a hidden single-diagnosis reveal.

## Source-Of-Truth Hierarchy Validation

### VERIFIED

Finding: master source-of-truth hierarchy is preserved.

Evidence: Batch 2 adds attending documentation, objective trend source, and MAR/action source without replacing verified medication reconciliation, pharmacy history, primary care, rheumatology, family, patient, or future consultant documentation.

Impact: source channels remain separate and traceable.

Action required: none before candidate review.

### VERIFIED

Finding: prednisone hierarchy remains preserved.

Evidence: FI-W10 explicitly introduces rheumatology as highest-authority taper intent by HD4, while FI-W13 shows that MAR actions do not prove pre-admission adherence or final steroid truth.

Impact: correct steroid reasoning still requires hierarchy reconstruction.

Action required: preserve in FI-W16 and FI-W20.

## Batch 1 Consistency Validation

### VERIFIED

Finding: Batch 2 remains consistent with FI-W01 through FI-W07.

Evidence: Batch 2 inherits the same identity, baseline function, comorbidity architecture, medication architecture, prednisone uncertainty, primary care baseline values, and FI-W06 timing constraints.

Impact: no locked Batch 1 file is contradicted.

Action required: none before candidate review.

### VERIFIED

Finding: insulin lispro exclusion from baseline medication architecture is preserved.

Evidence: FI-W13 marks insulin lispro as inpatient-only correctional coverage when needed and explicitly states it is not a baseline outpatient medication.

Impact: baseline medication count remains 20 and future inpatient glycemic-management reasoning remains available.

Action required: do not convert inpatient-only lispro into a baseline or discharge medication without later authorization.

## Anti-Answer-File Validation

### VERIFIED

Finding: no Batch 2 file functions as an answer file.

Evidence:

- FI-W08 does not settle diagnosis or medication restart.
- FI-W09 does not decide disposition.
- FI-W10 does not solve steroid contribution or consultant disagreement.
- FI-W11 does not create a final discharge plan.
- FI-W12 does not determine infection source, medication restart, or discharge safety.
- FI-W13 does not create a discharge medication list or final medication plan.

Impact: multi-document synthesis remains required.

Action required: preserve answer-file discipline during Batch 3 and Batch 4 construction.

## Unauthorized Content Check

### VERIFIED

Finding: no unauthorized FI-W IDs were created.

Evidence: constructed files are FI-W08 through FI-W13 only.

Impact: locked File Inventory v1 ID integrity is preserved.

Action required: do not create FI-W14 or later until Batch 3 is explicitly authorized.

### VERIFIED

Finding: no unauthorized task or grader artifacts were created.

Evidence: Batch 2 contains no task prompts, expected outputs, golden responses, grader guidance, AutoQC responses, DOCX artifacts, submission artifacts, RL Studio content, +7 information, or +30 information.

Impact: downstream phase boundaries remain intact.

Action required: none before candidate review.

## Candidate Review Risks

### PLAUSIBLE

Finding: FI-W12 values should be reviewed for realism and non-answer-file behavior.

Evidence: FI-W12 now contains objective values because Batch 2 is the authorized trend-source construction phase.

Impact: values strengthen reasoning but could drift toward over-determination if later files overuse them.

Action required: independent review should check whether FI-W12 supports reasoning without deciding medication restart or disposition.

### PLAUSIBLE

Finding: FI-W13 medication actions require later consultant context to be fully interpretable.

Evidence: FI-W13 intentionally records action patterns without final discharge recommendations.

Impact: later FI-W14-FI-W16 remain necessary to interpret time-sensitive consultant disagreement.

Action required: Batch 3 should preserve both consultant defensibility and MAR/source limitations.

### NO ISSUE

Finding: Batch 2 preserves closed-world and batch-gated construction doctrine.

Evidence: only FI-W08 through FI-W13 were created in candidate-review/batch-2. No FI-W14 through FI-W22, task-level files, supplementary files, prompts, goldens, grader guidance, AutoQC responses, or submission materials were created.

Impact: phase boundary remains intact.

Action required: stop before Batch 3.

### DISPUTED

Finding: Batch 2 should include final discharge medication recommendations or completed discharge outcome.

Evidence: locked construction plan prohibits answer-file drift and post-world information. FI-W11 and FI-W13 are intentionally pre-close, incomplete, and source-limited.

Impact: adding final recommendations would damage Trap #2 and Trap #5.

Action required: keep final discharge and medication-reconciliation outputs deferred.

## Final Status

Batch 2 Synthetic World-Level File Construction

Files Constructed:

FI-W08 through FI-W13

Status: CANDIDATE REVIEW
